SE-1003
Glaucoma / Ocular Hypertension
Phase 2Active
Key Facts
About Santen Pharmaceutical
Santen Pharmaceutical is a leading global player in the ophthalmology market, dedicated to addressing unmet medical needs in eye diseases. The company leverages its deep expertise in ocular drug delivery and formulation to build a diversified portfolio spanning glaucoma, retinal diseases, dry eye, and inflammation. With a long history of innovation and a commitment to research, Santen aims to contribute to the well-being of patients worldwide through its specialized ophthalmic solutions.
View full company profileTherapeutic Areas
Other Glaucoma / Ocular Hypertension Drugs
| Drug | Company | Phase |
|---|---|---|
| Tapros® (tafluprost) | Santen Pharmaceutical | Approved |
| Mirac® (ripasudil) | Santen Pharmaceutical | Approved |
| Catioprost® | Santen Pharmaceutical | Approved |
| Vyzulta (latanoprostene bunod) | Bausch Health | Approved |
| OTX-TIC (travoprost insert) | Ocular Therapeutix | Phase 1 |